Subject (B) | SE VA | ||||||||||
SE | Best-corrected VA BL | Day 0 | 3 weeks | 6 weeks | 12 weeks | 18 weeks | 24 weeks | 30 weeks | 36 weeks | VA Δ from BL | |
Intravitreal pegaptanib sodium | |||||||||||
1 | OD | 55 | 64 | 67 | 64 | 64 | 61 | 64 | 64 | * | 9 |
2 | OS | 83 | 80 | 83 | 86 | 86 | 79 | 84 | 77 | 85 | 2 |
3 | OD | 78 | 73 | 83 | 87 | 94 | 84 | * | * | * | 6 |
4 | OD | 86 | 89 | 88 | 85 | 89 | 90 | 87 | 89 | 90 | 4 |
5 | OS | 71 | 76 | 83 | 78 | 84 | 84 | 81 | 87 | 84 | 13 |
6 | OD | 68 | 77 | 72 | 76 | * | 85 | 88 | 88 | 83 | 15 |
7 | OS | 87 | 83 | 91 | 91 | 87 | 88 | 85 | 84 | 86 | −1 |
8 | OD | 68 | 72 | 81 | 77 | 84 | 84 | 79 | 79 | 79 | 11 |
9 | OS | 77 | 77 | 81 | 78 | 72 | 63 | 44 | 59 | 59 | −18 |
10 | OD | 85 | 88 | 89 | 89 | 87 | 87 | 81 | 58 | 88 | 3 |
Panretinal photocoagulation | |||||||||||
11 | OS | 61 | 60 | 59 | 66 | * | 64 | 64 | 73 | 74 | 13 |
12 | OD | 70 | 74 | 76 | 71 | 75 | 75 | 79 | 74 | 76 | 6 |
13 | OS | 82 | 78 | 76 | 78 | 74 | 76 | 79 | 68 | −14 | |
14 | OS | 81 | 86 | 82 | 83 | 81 | 82 | 77 | 68 | 68 | −13 |
15 | OD | 71 | 77 | 69 | 84 | 72 | 88 | 85 | 84 | 85 | 14 |
16 | OS | 80 | 87 | 63 | 84 | 83 | 58 | 76 | 83 | 85 | 5 |
17 | OS | 79 | 77 | 75 | 81 | 79 | 81 | 83 | 73 | 13 | −66 |
18 | OD | 82 | 83 | 77 | 83 | 71 | 84 | 83 | 79 | 78 | −4 |
19 | OD | 78 | 76 | 77 | 78 | 78 | 78 | 76 | 73 | 80 | −2 |
20 | OS | 68 | * | * | * | * | * | * | * | * | * |
Bold text: lost to follow-up; not included in analysis. Italic text: bilateral subjects.
*Patient did not attend this particular visit.
BL, baseline; OD, right eye; OS, left eye; SE, study eye.